Italia markets closed
Dow Jones
37.815,92 -570,17 (-1,49%) Nasdaq
15.657,82 -325,26 (-2,04%) Nikkei 225
38.405,66 +470,90 (+1,24%) EUR/USD
1,0676 -0,0049 (-0,46%) Bitcoin EUR
55.819,84 -3.169,92 (-5,37%) CMC Crypto 200
1.283,25 -55,81 (-4,17%)
Neurocrine Biosciences, Inc. (NBIX)
NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 04:00PM EDT
Dopo ore:
| Chiusura precedente | 138,89 |
| Aperto | 138,07 |
| Denaro | 137,37 x 600 |
| Lettera | 137,61 x 300 |
| Min-Max giorno | 137,34 - 140,47 |
| Intervallo di 52 settimane | 89,04 - 148,37 |
| Volume | |
| Media Volume | 890.980 |
| Capitalizzazione | 13,834B |
| Beta (5 anni mensile) | 0,28 |
| Rapporto PE (ttm) | 55,68 |
| EPS (ttm) | 2,47 |
| Prossima data utili | 01 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | 29 dic 1995 |
| Stima target 1A | 153,29 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.